In our hands, targeting macrophage recruitment in the glioma microenvironment with anti‐CSF1 treatment or decreasing macrophage VEGF production similarly accelerate tumor growth, but restore a functional and perfused blood vessel network that can support effective delivery of anti‐tumoral drugs. The gene discussed is VEGFA; the disease is central nervous system cancer.